Neurocrine Bioscience buy Morgan Stanley
Start price
12.06.24
/
50%
€124.65
Target price
12.06.25
€147.54
Performance (%)
-16.61%
Price
04.10.24
€103.95
Summary
This prediction is currently active. The prediction for Neurocrine Bioscience disappoints with a performance of -16.61%. This prediction currently runs until 12.06.25. The prediction end date can be changed by Morgan_Stanley at any time. Morgan_Stanley has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Neurocrine Bioscience | 0.873% | 0.873% |
iShares Core DAX® | -1.114% | 3.430% |
iShares Nasdaq 100 | 1.816% | 6.911% |
iShares Nikkei 225® | 2.113% | 5.501% |
iShares S&P 500 | 2.038% | 5.327% |
Comments by Morgan_Stanley for this prediction
In the thread Neurocrine Bioscience diskutieren
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $160.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Stopped prediction by Morgan_Stanley for Neurocrine Bioscience
Neurocrine Bioscience
Start price
Target price
Perf. (%)
€136.55
12.07.24
12.07.24
€155.89
12.07.25
12.07.25
-23.87%
04.10.24
04.10.24